Ingredient
Minoxidil
Minoxidil is flagged for pregnancy, breastfeeding and trying to conceive. The concern behind the strongest flag is known teratogen and fetal development.
- Rogaine
- Regaine
Verdict by profile
Truva checks every ingredient against six profiles. Jump to any of them for the full assessment.
- Strongest verdict
- Not Recommended
- Its verdict for pregnancy, the profile this one is worst in
- Profiles flagged
- 3 of 6
- Counting avoid, high risk and medium risk
- Irritancy
- 2 of 5
- Higher means more likely to sting or redden
Minoxidil and pregnancy
Not Recommended
- Known teratogen
- Fetal development
- Absorbed into the body
Minoxidil is a vasodilator medication used topically to promote hair growth, but it was originally developed as an oral blood pressure medication. While topical application results in lower systemic absorption than oral use, the drug still enters the bloodstream through the scalp. According to ACOG and the FDA, minoxidil is classified as pregnancy category C, meaning animal studies have shown adverse fetal effects. Studies in pregnant animals demonstrated decreased fetal weight and increased fetal deaths. While human data is limited, case reports suggest potential risks including cardiovascular effects on the fetus. The systemic absorption of topical minoxidil, though lower than oral forms, is still significant enough to raise concerns about fetal exposure. The FDA and most obstetricians recommend avoiding all forms of minoxidil during pregnancy due to potential teratogenic effects and unknown risks to fetal development. ACOG advises discontinuing minoxidil before conception and throughout pregnancy. Most dermatologists recommend postponing hair loss treatment until after pregnancy and breastfeeding are complete.
Minoxidil and breastfeeding
Not Recommended
- Passes into breast milk
- Infant exposure
- Absorbed into the body
Minoxidil is a vasodilator that promotes hair growth but also has systemic effects on blood pressure and cardiovascular function. The medication is absorbed through the scalp into the bloodstream and can accumulate in body tissues. According to the AAD and lactation experts, minoxidil passes into breast milk in clinically significant amounts. Animal studies show that oral minoxidil is excreted in breast milk, and while topical use results in lower systemic levels, transfer to milk still occurs. The concern is that minoxidil's cardiovascular effects could affect breastfed infants, potentially causing tachycardia or blood pressure changes. The FDA and LactMed database recommend avoiding minoxidil during breastfeeding. Most dermatologists and lactation consultants advise against using topical minoxidil while breastfeeding. The AAD recommends waiting until after weaning to resume hair loss treatments. If hair loss is a significant concern during the postpartum period, consulting with a dermatologist about breastfeeding-compatible alternatives is recommended.
Minoxidil and postpartum
Safe to Use
For postpartum women who are not breastfeeding, minoxidil can be an effective treatment for postpartum hair loss (telogen effluvium). This type of hair loss typically peaks around 3-4 months after delivery and can be distressing for new mothers. Minoxidil is well-studied and FDA-approved for hair regrowth. Since systemic absorption is the primary concern during pregnancy and breastfeeding, postpartum women who are not breastfeeding can safely use topical minoxidil. However, it's important to note that postpartum hair loss is usually temporary and resolves on its own within 6-12 months. Consistent use for several months is typically needed before seeing results with minoxidil.
Minoxidil and trying to conceive
Not Recommended
- Known teratogen
- Fetal development
- Builds up in tissue
Minoxidil is a vasodilator medication that is absorbed systemically through the scalp. While topical minoxidil has lower systemic absorption than oral forms, the drug can still accumulate in body tissues and remains detectable in the bloodstream for some time after discontinuation. According to ACOG and reproductive endocrinologists, women trying to conceive should discontinue minoxidil before attempting pregnancy. The FDA classifies minoxidil as pregnancy category C due to animal studies showing fetal harm. Since pregnancy often occurs before it's confirmed, continuing minoxidil while TTC could result in early fetal exposure during critical developmental windows. Most fertility specialists recommend stopping minoxidil at least one menstrual cycle before attempting conception to allow the drug to clear from your system.
Minoxidil and PCOS
Safe to Use
Women with PCOS often experience androgenic alopecia (female pattern hair loss) due to elevated androgen levels. Minoxidil is a vasodilator that promotes hair growth by improving blood flow to hair follicles and extending the growth phase of the hair cycle. Minoxidil is particularly beneficial for PCOS-related hair loss because it works independently of hormone levels. Unlike anti-androgen treatments, minoxidil doesn't interfere with hormones or insulin sensitivity, making it safe for women with PCOS who are not pregnant or trying to conceive. Clinical studies show that topical minoxidil effectively treats androgenic alopecia in women. Dermatologists frequently recommend minoxidil as a first-line treatment for hair loss in PCOS patients. It can be used alongside other PCOS treatments like metformin or spironolactone. However, women with PCOS who are trying to conceive should discontinue minoxidil before attempting pregnancy, as it must be stopped during pregnancy.
Minoxidil and general use
Safe to Use
- Irritant
Minoxidil is a well-established, FDA-approved treatment for hair loss in both men and women. It works as a vasodilator, improving blood flow to hair follicles and prolonging the growth phase of the hair cycle. Topical minoxidil is available over-the-counter in various formulations. For the general public, topical minoxidil is considered safe and effective when used as directed. The most common side effects are scalp irritation, dryness, and flaking. Some users experience an initial increase in hair shedding during the first few weeks, which typically resolves as new hair growth begins. Rare side effects include unwanted facial hair growth from inadvertent transfer and cardiovascular symptoms in sensitive individuals. The FDA has approved minoxidil for over-the-counter use, reflecting its favorable safety profile for most users. Consistent use for at least 4-6 months is typically required to see results, and discontinuation usually leads to gradual return of hair loss. People with cardiovascular conditions should consult a physician before use.
Everything else flagged for the same profiles
Related ingredients
Ingredients suggested in place of Minoxidil, each one with its own page here.
Ingredients that raise the same concerns.
Where this came from
Truva summarises published guidance from bodies including ACOG, the FDA, the EU SCCS and the Cosmetic Ingredient Review. It has no access to your medical history and it is not a substitute for your doctor, dermatologist or midwife. These assessments have not been reviewed by a clinician, and nothing here is a diagnosis or a prescription. If you are pregnant, breastfeeding or being treated for PCOS, take the ingredient list to the person looking after you.
Assessment last pulled from the ingredient database on .
One ingredient is the easy case.
A label has thirty of them. Truva reads the whole list at once and answers for the profile you set: pregnancy, breastfeeding, postpartum, trying to conceive, PCOS, or general use.
Download on theApp Store